The Research Antibodies Market is expected to register a CAGR of 5.5% during the forecast period. This is attributing to increasing investment in R&D, increasing research academies and industry collaborations, and a rise in proteomics and genomics research. As research antibodies are the essential component of biopharmaceutical and pharmaceutical research for the investigation of biological processes and to know the causes of diseases these antibodies play an important role. Thus, growing stem cells and neurobiology research around the globe with several product innovations and collaboration by the companies is fueling the growth of the market. For instance, in February 2019, a company ImmunoPrecise Antibodies LTD Collaborated with Foundation of Innovative New Diagnostic (FIND) to announce research collaboration project results in which they developed rabbit monoclonal antibodies using B cells select that helps in recognizing lipoarabinomannan (LAM) and biomarker for TB. Moreover, increasing incidences of neurodegenerative diseases such as multiple sclerosis and Parkinson's diseases leading to high demand of high-quality antibodies for neurobiology research and increasing demand of protein therapeutics, personalized medicines and development of novel drug is also some more factors that are anticipated to promote the research antibodies market in forecasted period.
Key Market Trends
Primary Antibodies in Research Antibodies is Estimated to Witness a Healthy Growth in Future.
Primary Antibodies are estimated to witness a healthy growth in future which is attributed to several benefits associated with these antibodies such as higher specificity, easy availability, suitable for research. These benefits leading to high adoption among biopharmaceutical and pharmaceutical companies. Moreover, primary antibodies are used for detection, measurement, and purification of biopharmaceuticals in several applications such as ELISA, flow cytometry, western blotting, and many more. Furthermore, with several usages in the detection of biomarkers for diseases such as cancer, Parkinson’s, diabetes, and Alzheimer's diseases leading to propel the segment growth.
In Addition, the growing number of biopharmaceutical research and development expenditure from past years will significantly propel the research antibodies market is forecasted period.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America is expected to hold a significant market share in the global Research Antibodies Market due to the increasing incidences of cardiovascular and blood diseases. As per The American Cancer Society, in 2018, approximately 1, 735,350 new cases of cancers were reported in the United States. This will increase the focus on cancer research and promote the demand of research antibodies market. Furthermore, rising R&D expenditure, a growing number of pharmaceutical and biopharmaceutical companies, technologically advanced research antibodies, and well-established infrastructure are also expected to fuel the Research Antibodies Market in this region.
The Research Antibodies Market is moderately competitive and consists of several major players. Some of the companies which are currently well-known in the market are Bio-Rad Laboratories, Inc., Abcam plc., Merck KGaA, Thermo Fisher Scientific, Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd, Lonza, PerkinElmer Inc., Cell Signaling Technology, Inc, and Agilent Technologies
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1.2 Scope of the Study
4.2 Market Drivers
4.2.1 Increasing Investment In R&D
4.2.2 Increase In Research Academies And Industry Collaborations
4.2.3 Rise In Proteomics And Genomics Research
4.3 Market Restraints
4.3.1 High Cost Of Research Antibodies
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1.1 Monoclonal Antibodies
5.1.2 Polyclonal Antibodies
5.2 By Source
5.3 By Product
5.4 By Application
5.4.2 Infectious Diseases
5.4.3 Stem Cells
5.5.1 North America
184.108.40.206 United States
220.127.116.11 United Kingdom
18.104.22.168 Rest of Europe
22.214.171.124 South Korea
126.96.36.199 Rest of Asia-Pacific
5.5.4 Middle-East and Africa
188.8.131.52 South Africa
184.108.40.206 Rest of Middle-East and Africa
5.5.5 South America
220.127.116.11 Rest of South America
6.1.1 Bio-Rad Laboratories, Inc.
6.1.2 Abcam plc.
6.1.3 Merck KGaA
6.1.4 Thermo Fisher Scientific
6.1.5 Becton, Dickinson and Company
6.1.6 F. Hoffmann-La Roche Ltd
6.1.8 PerkinElmer Inc.
6.1.9 Cell Signaling Technology, Inc
6.1.10 Agilent Technologies
A selection of companies mentioned in this report includes:
- Bio-Rad Laboratories, Inc.
- Abcam plc.
- Merck KGaA
- Thermo Fisher Scientific
- Becton, Dickinson and Company
- F. Hoffmann-La Roche Ltd
- PerkinElmer Inc.
- Cell Signaling Technology, Inc
- Agilent Technologies